Formulation of HBs antigen in Montanide ISA266 shows superiority to commercial HBsAg vaccine in the induction of humoral immune responses
Gastroenterology and Hepatology from Bed to Bench,
Vol. 12 No. 4 (2019),
1 September 2019
,
Page 292-300
https://doi.org/10.22037/ghfbb.v12i4.1496
Abstract
Aim: In the present study, a new formulation of HBsAg vaccine was developed and compared with a commercial peer.
Background: Vaccination of hepatitis B infection has been an unavoidable affair since the 1980s, though it has numerous limitations such as inefficacy in the induction of cellular immune responses. To address these limitations, research on novel formulations is necessary to develop a superior formulation with the potency of induction of both cellular and humoral immune responses.
Methods: HBsAg was formulated in oil-in-water adjuvant Montanide ISA-266 (5 µg/dose) using homogenizer. Balb/C mice were then immunized three times at days 0, 14, and 28 with HBsAg/Montanide ISA-266 or HBsAg/alum with proper control groups. Two weeks after the last immunization, immunological parameters including IL-2, IL-4, TNF-?, IFN-?, total IgG and IgG1/IgG2a isotypes were assessed by ELISA.
Results: The results demonstrated that the formulation of HBsAg with Montanide ISA-266 enhanced humoral immune responses versus the commercial vaccine and control groups. No significant difference in terms of Th1 pattern was found between HBsAg/Montanide ISA-266 and the commercial vaccine.
Conclusion: Formulation of HBsAg with an oil-based adjuvant may be useful for the induction of a more potent humoral immune response compared to the commercially available HBV vaccine.
Keywords: Adjuvant, Hepatitis B vaccine, Montanide ISA 266, Immune response.
(Please cite as Savoji MA, Haghighat S, Mirzaee M, Golkaran B, Mirzaee R, Esfandiari B, et al. Formulation of HBs antigen in Montanide ISA266 shows superiority to commercial HBsAg vaccine in the induction of humoral immune responses. Gastroenterol Hepatol Bed Bench 2019;12(4):292-300).
- Adjuvant
- Hepatitis B vaccine
- Montanide ISA 266
- Immune response.
How to Cite
References
2.Nguyen DH, Ludgate L, Hu J. Hepatitis B virus-cell interactions and pathogenesis. J Cell Physiol 2008;216:289-94.
3.Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
4.Thirion M, Ochiya T. Roles of micrornas in the Hepatitis B virus infection and related diseases. Virus 2013;5:2690-703.
5.Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol 2014;20:14559-67.
6.Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009;49:S13-21.
7. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. Chu CM1, Liaw YF. J Viral Hepat 2007;14:147-52.
8.Tan WS, Ho KL. Phage display creates innovative applications to combat hepatitis B virus. World J Gastroenterol 2014;20:11650-70.
9.Shoaei SD, Sali S, Karamipour M, Riahi E. Non-invasive histologic markers of liver disease in patients with chronic hepatitis B. Hepat Mon 2014;14.
10.Buxton JA, Kim JH. Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations. Can J Infect Dis Med Microbiol 2008;19:197-202.
11.Han K, Shao X, Zheng H, Wu C, Zhu J, Zheng X, et al. Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule. Hum Vaccin Immunother 2012;8:1845-9.
12.Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis 2012;12:966-76.
13.Nashibi R, Alavi SM, Yousefi F, Salmanzadeh S, Moogahi S, Ahmadi F, et al. Post-vaccination Immunity Against Hepatitis B Virus and Predictors for Non-responders Among Medical Staff. Jundishapur J Microbiol 2015;8:e19579.
14.Aghasadeghi MR, Banifazl M, Aghakhani A, Eslamifar A, Vahabpour R, Ramezani A. No evidence for occult HBV infection in hepatitis B vaccine non-responders. Iranian J Microbiol 2014;6:350-3.
15.Ricciardi A, Visitsunthorn K, Dalton JP, Ndao M. A vaccine consisting of Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG induces high level protection against murine schistosomiasis. BMC Infect Dis 2016;16:112.
16.Fakharzadeh S, Kalanaky S, Hafizi M, Goya MM, Masoumi Z, Namaki S, et al. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine. Vaccine 2013;31:2591-7.
17.Christiaansen AF, Schmidt ME, Hartwig SM, Varga SM. Host genetics play a critical role in controlling CD8 T cell function and lethal immunopathology during chronic viral infection. PLoS Pathog 2017;13:e1006498.
18.Ito H, Ando T, Nakamura M, Ishida H, Kanbe A, Kobiyama K, et al. Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand. J Viral Hepat 2017;24:155-62.
19.Roohvand F, Aghasadeghi MR, Sadat SM, Budkowska A, Khabiri AR. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun 2007;354:641-9.
20.Shokri M, Roohvand F, Alimohammadian MH, Ebrahimirad M, Ajdary S. Comparing Montanide ISA 720 and 50-V2 adjuvants formulated with LmSTI1 protein of Leishmania major indicated the potential cytokine patterns for induction of protective immune responses in BALB/c mice. Mol Immunol 2016;76:108-15.
21.Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002;1:111-8.
22.Jones TR, Obaldia N, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 1999;17:3065-71.
23.Jang SI, Kim DK, Lillehoj HS, Lee SH, Lee KW, Bertrand F, et al. Evaluation of montanide™ ISA 71 VG adjuvant during profilin vaccination against experimental coccidiosis. PloS One 2013;8:e59786.
24.Van Doorn E, Liu H, Huckriede A, Hak E. Safety and tolerability evaluation of the use of Montanide ISA51 as vaccine adjuvant: a systematic review. Hum Vaccin Immunother 2016;12:159-69.
25.Klimka A, Michels L, Glowalla E, Tosetti B, Kronke M, Krut O. Montanide ISA 71 VG is advantageous to Freund's adjuvant in immunization against S. aureus Infection of mice. Scand J Immunol 2015;81:291-7.
26.Fox CB, Baldwin SL, Vedvick TS, Angov E, Reed SG. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines Clin Vaccine Immunol 2012;19:1633-40.
27.Arevalo-Herrera M, Vera O, Castellanos A, Cespedes N, Soto L, Corradin G, et al. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am J Trop Med Hyg 2011;84:21-7.
28.Stark B, Andreae F, Mosgoeller W, Edetsberger M, Gaubitzer E, Koehler G, et al. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur J Pharm Biopharm 2008;70:153-64.
29.Jafari M, Moghaddam Pour M, Taghizadeh M, Masoudi S, Bayat Z. Comparative assessment of humoral immune responses of aluminum hydroxide and oil-emulsion adjuvants in Influenza (H9N2) and Newcastle inactive vaccines to chickens. Artif Cells Nanomed Biotechnol 2017;45:84-9.
30.Sebina I, Fogg LG, James KR, Soon MSF, Akter J, Thomas BS, et al. IL-6 promotes CD4(+) T-cell and B-cell activation during Plasmodium infection. Parasite Immunol 2017;39.
31.Mahdavi M, Ebtekar M, Khorram Khorshid HR, Azadmanesh K, Hartoonian C, Hassan ZM. ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses. Immunol Lett 2011;140:14-20.
32.Chen J, Pompano RR, Santiago FW, Maillat L, Sciammas R, Sun T, et al. The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials 2013;34:8776-85.
33.Thatte J, Rath S, Bal V. Analysis of immunization route-related variation in the immune response to heat-killed Salmonella typhimurium in mice. Infect Immun 1995;63:99-103.
34.Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 2010;185:5677-82.
- Abstract Viewed: 125 times
- PDF Downloaded: 108 times